The ARX gene (Aristaless-Related Homeobox) encodes a critical transcription factor essential for proper brain development and function. ARX is a member of the aristaless family of homeobox genes and plays a fundamental role in the development of the cerebral cortex, basal ganglia, and other brain regions. Mutations in ARX cause a spectrum of neurodevelopmental disorders ranging from lissencephaly to intellectual disability and epilepsy.
| Attribute |
Value |
| Gene Symbol |
ARX |
| Full Name |
Aristaless-Related Homeobox |
| Chromosomal Location |
Xp21.3 |
| NCBI Gene ID |
566 |
| Ensembl ID |
ENSG00000031081 |
| UniProt ID |
Q9NUJ1 |
| Gene Type |
Protein coding |
| OMIM |
300382 |
The ARX protein is a transcription factor containing a homeodomain for DNA binding. It functions primarily in the nucleus to regulate gene expression during development and in adult tissues. The protein contains multiple functional domains including the homeobox, prd-like homeodomain, and various regulatory motifs.
- Homeodomain: DNA-binding helix-turn-helix motif (60 amino acids)
- Polyalanine Tracts: Expansion causes some disease variants
- Octapeptide Domain: Transcription regulation
- Nuclear Localization Signal: Directs nuclear localization
ARX plays critical roles in development and function:
- Cortical Development: Regulates neuronal migration and differentiation
- GABAergic Interneuron Development: Essential for interneuron specification
- Basal Ganglia Development: Critical for striatal and pallidal development
- Pancreatic Development: Role in islet cell function
- Testicular Function: Involved in testis development
- GABA Biosynthesis: GAD1, GAD2 (glutamate decarboxylase)
- Transcription Factors: Lhx6, Lhx8 (interneuron specification)
- Signaling Molecules: Shh, Dlx genes
- Severe brain malformation
- Abnormal genitalia in males
- Early-onset seizures
- Profound developmental delay
- Various ARX mutations cause ID and seizures
- Spectrum of severity
- Often includes infantile spasms
- May have associated features
- Partington Syndrome: Mild ID with movement disorder
- Proud Syndrome: Agenesis of corpus callosum with genital anomalies
- Early infantile epileptic encephalopathy: EIEE1 associated with ARX
| Variant |
Type |
Effect |
| P353L |
Missense |
Loss of DNA binding |
| G362fs |
Frameshift |
Truncated protein |
| 433_452dup |
Duplication |
Polyalanine expansion |
| 330_360del |
Deletion |
Polyalanine deletion |
- Missense mutations (DNA binding domain)
- Frameshift/nonsense mutations
- Polyalanine expansions (25-30 repeats)
- Whole gene deletions
- Gene Therapy: AAV-mediated ARX delivery
- Transcription Factor Modulators: Small molecules affecting ARX activity
- Target Gene Modulation: Upstream/downstream pathway targeting
- Symptomatic Treatment: Seizure control, supportive care
- Gene replacement being explored in models
- Understanding of ARX functions advancing
- Stem cell approaches in development
- Mouse models available for testing
- X-linked location (male predominance)
- Multiple clinical phenotypes
- Brain delivery of therapeutics
- Early intervention needed
| Partner |
Interaction |
| Dlx1/2 |
Cooperative transcription |
| Lhx6 |
Interneuron development |
| Ldb1 |
Transcriptional cofactor |
| Groucho/TLE |
Transcriptional repression |
- GAD1/2 (GABA synthesis)
- Nkx2-1 (ventral telencephalon)
- Lhx6/Lhx8 (interneuron migration)
- SHH signaling (Sonic Hedgehog)
- Wnt signaling
- GABAergic differentiation pathways
Current research focuses on:
- Understanding ARX functions in specific neuronal populations
- Developing therapeutic approaches
- Creating better model systems
- Identifying downstream pathways
- Exploring early intervention strategies